A fresh look at extended-duration anticoagulation after venous thromboembolism
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20260106
Abstract
No abstract availableFunding Information
- indústria farmacêutica
This publication has 5 references indexed in Scilit:
- Apixaban for Extended Treatment of Provoked Venous ThromboembolismNew England Journal of Medicine, 2025
- Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trialThe Lancet, 2025
- Risk of recurrent venous thromboembolism according to baseline risk factor profilesBlood Advances, 2018
- Rivaroxaban or Aspirin for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2017
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010